Taiho Ventures co-led a series A round for the MIT spinout, which was incubated by MPM Capital.

US-based circular RNA therapy developer Orna Therapeutics launched with more than $100m in funding yesterday to commercialise research undertaken at Massachusetts Institute of Technology.
The total includes an $80m series A round co-led by Taiho Ventures, the corporate venturing unit of pharmaceutical firm Taiho, F2 Ventures and MPM Capital.
Pharmaceutical firms Astellas, Gilead and Novartis took part through Astellas Venture Management, Kite Pharma and Novartis Institutes for Biomedical Research respectively, investing alongside Pags Group.
The company previously…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in